On May 6th, NICE will publish their recommendation (ACD) for the MTA (multi technology appraisal) of dasatinib, nilotinib and high dose imatinib (600-800mg) for treatment of imatinib resistant CML in chronic phase.
You will be able to comment on the decision through the NICE website on that day. CML Suport Group will publish a press release on the same date.
Sandy